GALECTIN THERAPEUTICS INC - 10-Q Filing

Galectin Therapeutics reports Q3 2026 net loss of $3.5M and significant debt-to-equity conversion totaling 34.4 million shares.

SEC EDGAR ·

Tickers: $GALT

Read the full article at SEC EDGAR

More Regulatory news